巴克特林诱导的肝毒性
Henry Onyirimba1, Ava L Boudi2, Max Boudi3
1Medicine, Banner Health, Phoenix, USA.
Cureus
|December 23, 2024
概括
硫甲醇/trimethoprim (SMX/TMP),一种抗生素,很少会导致肝损伤 (肝毒性). 这种病例突出了一个患者,在服用SMX/TMP治疗尿路感染后出现黄和肝酶升高.
科学领域:
- 药理学 药理学 是一个学科.
- 肝病学 肝病学是一种肝病学.
- 传染性疾病 传染性疾病
背景情况:
- 硫索/trimethoprim (SMX/TMP) 是一种广泛使用的抗生素,用于治疗各种细菌感染,包括尿路感染 (UTI).
- 虽然SMX/TMP通常是安全的,但与罕见但严重的不良反应有关,特别是肝毒性,这可能导致肝衰竭.
- 由于SMX/TMP的肝毒性很少被认可,特别是在尿路感染等常见症状的背景下.
研究的目的:
- 报告一种罕见的药物诱导性肝损伤 (肝毒性) 病例,该病例是由硫甲醇/trimethoprim (SMX/TMP) 引起的.
- 提高SMX/TMP诱导的肝毒性作为患有黄和肝酶升高的患者潜在的不良反应的认识.
- 强调在肝损伤的差异诊断中考虑药物副作用的重要性.
主要方法:
- 使用案例研究方法,重点关注单个患者的临床表现和治疗过程.
- 获得了详细的病史,包括药物使用情况.
- 记录了临床发现,实验室结果 (肝酶,胆红素) 和治疗结果.
主要成果:
- 一名43岁的男性患者在开始SMX/TMP治疗前列腺炎性尿路感染后一周后出现黄和肝酶显著升高.
- 这位患者以前没有病史,也没有同时服用可能解释肝损伤的药物.
- 停止SMX/TMP和支持性护理导致肝功能在几周内逐渐恢复.
结论:
- 硫甲醇/三甲 (SMX/TMP) 可能导致罕见但严重的肝毒性,即使在没有先前存在的病症的患者中也是如此.
- 早期识别和撤销违规剂对于管理SMX/TMP诱导的肝损伤至关重要.
- 这一案例强调了临床医生在评估无法解释的肝炎患者时,需要保持对药物诱导肝损伤的高怀疑指数.
相关概念视频
Hepatic Drug Excretion: Enterohepatic Cycling
996
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
996
Hepatic Drug Excretion: Influencing Factors
80
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
80
Drug Biotransformation: Overview
2.3K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.3K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
141
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
141
Combined Effects of Drugs: Synergism
3.7K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
3.7K
Inflammatory Bowel Disease I: Ulcerative Colitis
135
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
135


